Cellogen Therapeutics, a Bengaluru-based biotech startup, has raised ₹20 Crore (approximately $2 million) from Kotak Alternate Asset Managers (Kotak Alts). This funding marks a significant step for the startup, which is focused on advancing its CAR‑T clinical programs and expanding its gene therapy pipeline. The investment highlights growing interest and support for innovations in life sciences and health tech sectors in India.
### Cellogen Therapeutics’ Vision and Innovation
Founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad, Cellogen Therapeutics is at the forefront of developing next-generation therapies using Chimeric Antigen Receptor T (CAR-T) cells. These therapies are designed to treat cancers and blood disorders, with the goal of making such life-saving treatments more affordable. While conventional CAR-T therapies can cost between $500,000 and $700,000, Cellogen aims to offer its treatments at a significantly reduced price range of $60,000 to $70,000.
The startup’s innovative approach lies in its bispecific, dual-antigen CAR-T platform, which targets two different markers on cancer cells. This method is not only more effective but also reduces the likelihood of cancer relapse compared to existing single-marker CAR-T treatments. Cellogen is gearing up for phase I human clinical trials, pending regulatory approvals, in collaboration with CMC Vellore. The company has also secured a patent for its CAR-T platform, further solidifying its position in the biotech landscape.
### The Biotech Funding Landscape
The investment from Kotak Alts comes through its Kotak Life Sciences Fund I (KLSF-I), which focuses on early- and growth-stage lifescience and healthtech ventures. This fund had its first close in January last year, amassing ₹250 Crore (around $29 million) from family offices, ultra-high-net-worth individuals, and industry veterans. The fund’s investment strategy spans the entire lifecycle of biotech startups, including early, growth, and late-stage investments.
Cellogen’s recent funding round follows a ₹15 Crore investment from Hyderabad-based Natco Pharma, which acquired over a 5% stake in the startup. These investments underscore the increasing confidence in India’s burgeoning biotech sector, which is home to over 11,000 startups. This growth is further bolstered by government initiatives aimed at promoting research, manufacturing, and innovation in the biotech space.
### Implications for India’s Startup Ecosystem
Cellogen Therapeutics’ funding is indicative of a broader trend of rising investments in Indian biotech startups. The sector’s rapid growth is fueled by technological advancements and a supportive funding environment, attracting both domestic and international investors. Startups like Cellogen are crucial in pushing the boundaries of medical research and treatment options, offering new solutions to age-old health challenges.
As the biotech sector continues to expand, it presents numerous opportunities for entrepreneurs, investors, and researchers. The focus on making cutting-edge treatments more accessible aligns with India’s broader healthcare goals and could potentially lead to collaborative efforts with international biotech firms.
Looking ahead, Cellogen Therapeutics aims to continue its clinical advancements and expand its gene therapy offerings. For investors and stakeholders in the Indian biotech sector, it will be critical to observe how Cellogen navigates regulatory challenges and scales its operations while maintaining affordability and efficacy of its treatments. This will set a precedent for future innovations and investments in the life sciences domain in India.
